Cytrx Stock News

Profitability This table compares LadRx and Sorrento Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets LadRx N/A -67.61% -45.39% Sorrento

Volatility and Risk SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, indicating that its share p

Institutional and Insider Ownership 0.1% of LadRx shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 12.8% of LadRx sh

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as

LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics,

LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics,

CytRx (CYTR) said it would merge with its subsidiary Centurion BioPharma as the company looks to benefit from Centurion''s LADR platform, which is being developed for localized delivery…

Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability. Volatility & Risk Vir Biotechnology has a beta of -1.48, suggesting that its stock price is 248% []

Vir Biotechnology and CytRx are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst

Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Volatility and Risk Vir Biotechnology has a beta of -1.48, indicating that its stock price is 248% [] The post Financial Survey: Vir Biotechnology (NASDAQ:VIR) vs. CytRx (OTCMKTS:CYTR) appeared first on ETF Daily News .

Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Profitability This table compares Vir Biotechnology and CytRxs net margins, return on equity and return on assets. [] The post Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) Critical Contrast appeared first on ETF Daily News .

Vaxcyte (NASDAQ:PCVX) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Analyst Recommendations This is a breakdown of recent ratings and price targets for Vaxcyte and CytRx, as []

CytRx (OTCMKTS:CYTR) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Institutional and Insider Ownership 0.1% of CytRx shares are owned by institutional investors. Comparatively, 60.2% []

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks,

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro